Literature DB >> 18522793

The usefulness of delayed enhancement magnetic resonance imaging for diagnosis and evaluation of cardiac function in patients with cardiac sarcoidosis.

Fumitaka Matoh1, Hiroshi Satoh, Katsunori Shiraki, Keiichi Odagiri, Takeji Saitoh, Tsuyoshi Urushida, Hideki Katoh, Yasuo Takehara, Harumi Sakahara, Hideharu Hayashi.   

Abstract

OBJECTIVES: Cardiac involvement is an important prognostic factor in patients with sarcoidosis. We evaluated the usefulness of delayed enhancement MRI (DE-MRI) for diagnosing cardiac sarcoidosis by comparing with nuclear imaging and studying the correlation between DE area and left ventricular (LV) function.
METHODS: Twelve patients (male:female 3:9) diagnosed as having sarcoidosis underwent Gd-MRI, myocardial perfusion SPECT (Tl-201, Tc-99m sestamibi), Ga-67 scintigraphy, and/or F-18 FDG-PET.
RESULTS: DE was observed in 5 patients, and was positive in 39 (39%) of 100 LV segments. The corresponding perfusion defects in myocardial perfusion SPECT were undetectable in 14 (36%) segments. DE distributed mainly in mid- to epi-myocardium, and the lack of perfusion defects in myocardial perfusion SPECT was more prominent in less transmural DE segments. Two patients with diffuse DE and 1 case with focal DE exhibited positive cardiac uptake in Ga-67 scintigraphy, and 2 other cases with focal DE showed cardiac uptake in F-18 FDG-PET. In 7 patients without DE, there were no significant findings in nuclear imaging. Both LV end-diastolic and end-systolic volume were positively and LV ejection fraction was negatively correlated with the extent of DE area. Four patients treated with corticosteroid showed improvement in nuclear imaging and slight decreases in DE area but no recovery in LV function.
CONCLUSIONS: DE-MRI is useful to diagnose the cardiac involvement of sarcoidosis and to evaluate cardiac function. It is likely that the distribution of DE in mid- to epi-myocardium is the characteristic of cardiac sarcoidosis, and the larger DE area may be correlated with poor LV function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18522793     DOI: 10.1016/j.jjcc.2008.03.002

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  19 in total

Review 1.  Identifying the etiology: a systematic approach using delayed-enhancement cardiovascular magnetic resonance.

Authors:  Annamalai Senthilkumar; Maulik D Majmudar; Chetan Shenoy; Han W Kim; Raymond J Kim
Journal:  Heart Fail Clin       Date:  2009-07       Impact factor: 3.179

Review 2.  Distribution of late gadolinium enhancement in various types of cardiomyopathies: Significance in differential diagnosis, clinical features and prognosis.

Authors:  Hiroshi Satoh; Makoto Sano; Kenichiro Suwa; Takeji Saitoh; Mamoru Nobuhara; Masao Saotome; Tsuyoshi Urushida; Hideki Katoh; Hideharu Hayashi
Journal:  World J Cardiol       Date:  2014-07-26

3.  Multimodality imaging in the diagnosis and management of cardiac sarcoidosis.

Authors:  Shant J Manoushagian; Vladimir Lakhter; Pravin V Patil
Journal:  J Nucl Cardiol       Date:  2016-11-11       Impact factor: 5.952

4.  [Clinical indications for the use of cardiac MRI. By the SIRM Study Group on Cardiac Imaging].

Authors:  E Di Cesare; F Cademartiri; I Carbone; A Carriero; M Centonze; F De Cobelli; R De Rosa; P Di Renzi; A Esposito; R Faletti; R Fattori; M Francone; A Giovagnoni; L La Grutta; G Ligabue; L Lovato; R Marano; M Midiri; A Romagnoli; V Russo; F Sardanelli; L Natale; J Bogaert; A De Roos
Journal:  Radiol Med       Date:  2012-11-26       Impact factor: 3.469

5.  Investigation of cardiomyopathy using cardiac magnetic resonance imaging part 1: Common phenotypes.

Authors:  Shaunagh McDermott; Ailbhe C O'Neill; Carole A Ridge; Jonathan D Dodd
Journal:  World J Cardiol       Date:  2012-04-26

Review 6.  ¹⁸F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis.

Authors:  Hiroshi Ohira; Ichizo Tsujino; Keiichiro Yoshinaga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-11       Impact factor: 9.236

Review 7.  Pathophysiology and clinical management of cardiac sarcoidosis.

Authors:  Nabeel Hamzeh; David A Steckman; William H Sauer; Marc A Judson
Journal:  Nat Rev Cardiol       Date:  2015-02-24       Impact factor: 32.419

Review 8.  Extrapulmonary manifestations of sarcoidosis.

Authors:  Deepak A Rao; Paul F Dellaripa
Journal:  Rheum Dis Clin North Am       Date:  2013-03-13       Impact factor: 2.670

Review 9.  Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment.

Authors:  Joseph P Lynch; Jennifer Hwang; Jason Bradfield; Michael Fishbein; Kalyanam Shivkumar; Roderick Tung
Journal:  Semin Respir Crit Care Med       Date:  2014-07-09       Impact factor: 3.119

Review 10.  Updates on the Role of Imaging in Cardiac Sarcoidosis.

Authors:  Yan Yatsynovich; Damian Valencia; Mikhail Petrov; Juan David Linares; Mufti M Rahman; Nathaniel Dittoe
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.